CPT1C and neoplasm: Therefore—and even though high CPT1C expression has been demonstrated to trigger tumour growth and metastasis in different mice models [10,12,13,26], and to be associated with low OS for several human tumours [24,26]—CPT1C downregulation does not seem to be an appropriate strategy for HER2+ and TNBC since it leads to senescence and anthracyclines chemoresistance.